Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 36 of 40

Conclusions (2 of 2)

Most osteoporosis interventions have notable adverse effects that should be taken into account in decisionmaking.

Dosing frequency appears to affect adherence and persistence, with weekly doses having improved adherence over daily regimens.

Limited evidence suggests that treatment extended beyond 5 years can provide additional reductions in vertebral fracture risk (measured at 10 years). For nonvertebral fractures, post-hoc analysis found reduction in risk only for women who had osteoporosis or prevalent vertebral fractures at five years of treatment.

Monitoring BMD during therapy does not fully reflect treatment benefits, as patients with BMD losses during antiresorptive therapy may still experience reduced fracture risk.